Abbott Labs (NYSE:ABT) has never been shy about using M&A to build its business, and it was generally assumed that more deals would follow in the wake of the company's split with AbbVie (Nasdaq:ABBV). While Monday is often the preferred day to announce deals, Abbott went above and beyond this week with two acquisition announcements – both of which could be highly promising down the line.
A Better Mousetrap For The Legs?
Peripheral vascular treatment is still a high-growth market, as clinicians have an increasing array of effective tools at hand to treat blockages in the arteries of the legs – blockages that can lead to falls and amputations if not treated. Major coronary stent players like Abbott, Medtronic (NYSE:MDT), and Boston Scientific (NYSE:BSX) also develop stents for the peripheral vasculature (where they also compete with the likes of Covidien (NYSE:COV), Bard (NYSE:BCR), Johnson & Johnson (NYSE:JNJ), and Cook), but stents have long been problematic in these narrower, twisting vessels, and stents have to compete with various arthrectomy devices sold by companies including Covidien, Cardiovascular Systems (Nasdaq:CSII), and Spectranetics (Nasdaq:SPNC).
Abbott is bulking up its business here with the acquisition of IDev Technologies for $310 million. IDev has developed its SUPERA Veritas peripheral stent system, and it looks quite promising. These stents use a proprietary interwoven wire technology that attempts to mimic a more natural motion. 
So far, it looks like there's something to this technology. While peripheral stents have historically had fracture rates approaching 50% and high incidiences of restenosis (though more modern versions are much, much better), studies of the VERITAS have shown solid long-term patency and as little as zero fractures, even in what should otherwise be very difficult cases. If the data hold up, this could be a compelling peripheral platform for Abbott in a relatively short amount of time, but the stent is not yet approved for the U.S.
SEE: A Checklist For Successful Medical Technology Investment

A New Approach To A Common Procedure
Abbott has also announced the acquisition of OptiMedica, a privately-held med-tech company that has developed the Catalys Precision Laser System for cataract surgery. The Catalys uses a combination of a laser, optical coherence tomography, and pattern scanning technology to replace many of the manual steps in a cataract surgery procedure. While cataract surgery has become relatively routine, complications do tend to be associated with the various manual steps of the process, and this system could offer improvements in throughput and patient outcomes. Better still, it fills that sweet-spot in tech of “new ways of doing old things”.
Abbott will be paying $350 million upfront, with milestones worth as much as $150 million tied to sales. This acquisition should fit in well with Abbott's existing eye care business, and with the recent Valeant (NYSE:VRX) acquisition of Bausch & Lomb, this could be a good opportunity to gain share in the cataract surgery market. 
Two In, One Out
Although not packaged in with Monday's deal announcements, word has also come out that the company has ended its partnership with Stratec Biomedical. There was never all that much information on this partnership, other than that they were collaborating on some sort of automated analyzer systems for the diagnostics market. With Stratec attributing the decision to a change in Abbott's priorities, I wonder if this will lead to speculation that Abbott is deprioritizing the diagnostics business (though I'd think that's a bit of a leap at this point...).
The Bottom Line
With Abbott reporting later this week, I'll be back with a more complete discussion of valuation and Abbott's investment prospects at that time. For now, though, I would say that both of these acquisitions look like good uses of capital and both deals represent potentially transformative technologies in large and meaningful markets where Abbott already has a presence – a detail which should increase the odds of success down the line.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  3. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  4. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  5. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  6. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  7. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  8. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  9. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
  10. Investing News

    Alphabet Earnings Beat Expectations (GOOGL, AAPL)

    Alphabet's earnings crush analysts' expectations; now bigger than Apple?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. How long does it take to execute an M&A deal?

    Even the simplest merger and acquisition (M&A) deals are challenging. It takes a lot for two previously independent enterprises ... Read Full Answer >>
Trading Center